A*STAR Singapore Immunology Network (A*STAR SIgN)
A rosy view of malaria research
28 Jan 2021Flower-like ‘rosettes’ may help malaria parasites evade the body’s immune defences.
No two cells are alike
18 Jan 2021A comprehensive ranking of 14 algorithms may help bioinformaticians overcome inconsistencies during data collection.
Reducing uncertainty about COVID-19
11 Jan 2021A multifaceted study by the Singapore 2019 Novel Coronavirus Outbreak Research team is filling in some of the gaps left in the urgent quest to understand COVID-19 infection.
Predicting severe cases of COVID-19
28 Dec 2020A*STAR researchers identify new, specific markers of severe COVID-19 that may improve the management and treatment of patients.
An indelible memory of dengue
26 Oct 2020New clues into how the immune system remembers a dengue infection may lead to a better vaccine.
Staying ahead of the (infection) curve
30 Sep 2020Serology testing may be fast and easy to perform, but there are still some limitations that need to be overcome, suggests Laurent Renia.
A fatal flaw in the immune system
28 Sep 2020Clinicians and scientists have discovered a rare mutation that impairs the immune system, and are using their findings to devise treatment strategies
The immune system remembers
16 Sep 2020The presence of memory T cells in COVID-19-recovered patients hints at their importance in COVID-19 immunity.
Placing a ‘hit’ on the crown
11 Sep 2020Could there be a drug that can both treat and protect against COVID-19? The answer may be found in antibody drugs, a promising therapeutic modality against the coronavirus.
Turning immunotherapy inside out
31 Aug 2020A novel targeting strategy may make pave the way for effective cancer immunotherapy against previously ‘undruggable’ targets.
To control outbreaks, go back to basics
28 Aug 2020Two coronavirus experts suggest that the best way to control an outbreak may be to first understand viral biology and behavior in animals and humans.
The mutation making COVID-19 milder
24 Aug 2020Scientists at A*STAR have found that a mutation in SARS-CoV-2 called ∆382 leads to milder clinical outcomes, with implications for COVID-19 treatments and vaccines.